Clinical trial results of Platinib (Pujihua) in terms of tumor shrinkage rate

Pralsetinib is a highly selective RETkinase inhibitor, mainly used to treat non-small cell lung cancer (NSCLC) and thyroid cancer with RET gene fusion or mutation. Traditional chemotherapy and immunotherapy have limited efficacy in such patients, and RET fusion-driven tumors are more responsive to targeted inhibitors. Therefore, platinib has been focused on evaluating its objective response rate (ORR) and tumor shrinkage in multiple clinical trials around the world, with a view to providing more effective treatment options for this precise population.

In the ARROWpivotal clinical trial, platinib showed significant efficacy in patients with RET fusion-positive metastatic non-small cell lung cancer. For the patient population that has received previous treatment (such as progression after chemotherapy), the objective response rate (ORR) of platinib reaches approximately 62%, among which the proportion of partial response (PR) is close to that of all responders, and complete response (CR) is rare but has also been reported. For untreated RETfusion-positive NSCLC patients, ORR is higher, reaching about 79%, and the median response time exceeds 17 months, showing the powerful ability of platinib to shrink tumors in first-line treatment.

In addition to lung cancer, platinib has also shown good efficacy in RETmutated medullary thyroid carcinoma (MTC) and RETfusion-positive papillary thyroid carcinoma (PTC). Clinical data show that in patients with RET mutationsMTC, the ORR of platinib is about 60%, and in RETfusion-positive PTC patients, ORR was as high as 75% is around, and the onset of tumor shrinkage is usually within weeks to months after the start of treatment. In addition, in some rare RET fusion-positive solid tumors, platinib has also been observed to significantly reduce tumor volume, further expanding its clinical application prospects.

Overall, platinib has demonstrated a high tumor shrinkage rate and durable response in multiple RET positive tumor types, especially in untreated people. This result not only provides new treatment hope for RET-driven patients, but also promotes the development of precision medicine in the fields of lung and thyroid cancer. With the release of more long-term follow-up data, platinib is expected to become the first-line standard treatment drug for RET-positive patients in the future, and form a combination regimen with other targeted drugs or immunotherapy to further improve the efficacy.

Reference materials:https://www.drugs.com/